A Phase 2 interventional study of Vi-DT Vaccine and Vi Polysaccharide Vaccine in Safety Issues and Immunogenicity, sponsored by PT Bio Farma. Completed at 2 sites in Indonesia. Open to participants aged 6 Months to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-20.
Sponsored by PT Bio Farma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to assess the safety and immunogenicity of Vi-DT vaccine in adults, adolescent, children and infants.
To describe the safety of this vaccine following one dose immunization in adults, adolescent, children and infants.
To assess immunogenicity following one dose of Vi-DT vaccine immunization. To compare the safety and immunogenicity of Vi-DT to Vi polysaccharide vaccine in adults, adolescents, and children groups.
To compare the safety and immunogenicity of Vi-DT to IPV vaccine in infants groups.
Kinetics of Vi-specific IgG antibodies up to 6 months and 1 year after administration of 1 dose of vaccine.
To evaluate the safety and immunogenicity of Vi-DT co-administered with MR vaccine in infants (≥ 9months -23 months old).
To evaluate the safety and immunogenicity of MR vaccine co-administered with Vi-DT vaccine in infants (≥ 9months -23 months old).
PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria For adults-adolescent-children:
Exclusion Criteria for infants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 dose of 0.5 ml Vi-DT vaccine
Biological: Vi-DT Vaccine
1 dose of 0.5 ml Vi polysaccharide vaccine
Biological: Vi Polysaccharide Vaccine
1 dose of 0.5 ml Vi-DT vaccine
Biological: Vi-DT Vaccine
1 dose of 0.5 ml Vi polysaccharide vaccine
Biological: Vi Polysaccharide Vaccine
1 dose of 0.5 ml Vi-DT vaccine
Biological: Vi-DT Vaccine
1 dose of 0.5 ml IPV vaccine
Biological: IPV Vaccine
1 dose of Vi-DT Vaccine
Also known as: Typhoid Conjugate Vaccine
1 dose of Vi Polysaccharide Vaccine
1 dose of IPV Vaccine
Local reaction and systemic event after vaccination
Percentage of subjects with at least one immediate reaction (local reaction or systemic event) after vaccination.
Time frame: 28 days
Adverse events after vaccination
Percentage of subjects with at least one of these adverse events, solicited or not, within 24 h, 48h, 72h and 28 days after 1 dose vaccination.
Time frame: up to 28 days
Serious adverse events after vaccination
Number and percentage of subjects with serious adverse event from inclusion until 28 day after vaccination
Time frame: 28 days
Geometric Mean Titers (GMT)
Geometric Mean Titers (GMT) 28 days following immunization
Time frame: 28 days
Percentage of subjects with increasing antibody titer >= 4 times
Percentage of subjects with increasing antibody titer \>= 4 times in all subjects
Time frame: 28 days
Ran from Jul 2018 to primary completion in Dec 2019, 17 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.